Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
Key Highlights
- ➤FDA approves CardioMEMS updates enabling patient access to pulmonary artery pressure readings
- ➤CardioGuide HF App delivers PAP trends on patients’ iOS or Android smartphones
- ➤Dynamic Treatment Plan sends personalized medication adjustment instructions through the app
- ➤Abbott plans CardioGuide HF App and Dynamic Treatment Plan availability later this year
Expert Statements
Andrew J. Sauer, M.D., Cardiologist and vice president for research at Saint Luke's Mid America Heart Institute; professor of medicine at the University of Missouri-Kansas City
“Heart failure can worsen before patients notice shortness of breath, swelling or weight gain. Pulmonary artery pressure readings can help identify changes earlier, giving care teams an opportunity to adjust treatment before symptoms develop.”
Andrew J. Sauer, M.D., Cardiologist and vice president for research at Saint Luke's Mid America Heart Institute; professor of medicine at the University of Missouri-Kansas City
“By giving patients access to their pressure trends and personalized guidance from their care team, the CardioGuide HF App can help patients better understand their condition, understand why treatment adjustments are recommended, and take a more active role in managing their heart failure.”
Katie Spayde, Vice president of Abbott's heart failure division
“Abbott is reshaping heart failure care by bringing meaningful, actionable information directly to patients.”
Katie Spayde, Vice president of Abbott's heart failure division
“For many people living with heart failure, managing their condition is part of everyday life. By giving patients greater visibility into their condition, these new capabilities help them stay informed, engaged and connected to their care between doctor visits.”
Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition PR Newswire
* For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App * Rising PAP can signal worsening heart failure weeks before patients experience symptoms * New capabilities help patients take a more active role in their care and stay connected to their care teams between doctor visits ABBOTT PARK, Ill., Oct. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App. For the first time, care teams can allow U.S. CardioMEMS patients to view their pulmonary artery pressure (PAP) readings directly on their smartphones, giving them greater insight into their condition and helping them take a more active role in their care.
Get started
Create a free account to read the full story.